Section Arrow
MBIO.NASDAQ
- Mustang Bio Inc
(Financial Status)
Quotes are at least 15-min delayed:2026/09/03 13:41 EDT
Regular Hours
Last
 0.5609
+0.0179 (+3.30%)
Day High 
0.5609 
Prev. Close
0.543 
1-M High
0.6531 
Volume 
28.49K 
Bid
0.544
Ask
0.5609
Day Low
0.5432 
Open
0.5432 
1-M Low
0.5304 
Market Cap 
4.11M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 0.55 
20-SMA 0.57 
50-SMA 0.62 
52-W High 1.85 
52-W Low 0.524999 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.42/-0.35
Enterprise Value
4.11M
Balance Sheet
Book Value Per Share
1.00
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
RAREUltragenyx Pharmaceutical14.54-11.99-45.19%-- 
ATAIAtaiBeckley Inc7.395+0.045+0.61%-- 
AIMAIM ImmunoTech Inc.0.243+0.0084+3.58%-- 
GERNGeron Corp1.515-0.075-4.72%-- 
SMMTSummit Therapeutics17.045+2.445+16.75%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.